胱抑素C与尿微量蛋白及尿β2-MG联合检测在恶性肿瘤化疗中的应用价值  

Detection of Serum Cystatin C, Microalbuminuria and Urine β2-microglobin in the Cancer Chemotherapy

作　　者：陈红涛[1] 张红雨[2] 舒晓春[1] 王亨莉[1] 

机构地区：[1]中山大学附属第五医院检验科,519000 [2]中山大学附属第五医院肿瘤化疗科,519000

出　　处：《中国临床实用医学》2009年第8期63-65,共3页China Clinical Practical Medicine

摘　　要：目的探讨尿β2-微球蛋白（β2-microglobin，β2-MG）、尿微量白蛋白（Microalbuminuria，MA）及血清CysC与血清尿素（blood Urea）、肌酐（cr）联合检测在化疗中对肾功能评价的临床意义。方法将50例恶性肿瘤患者，分别在化疗前、化疗后1d、3d、7d和15d时测定血清CysC与UREA、Cr同时检测尿β2-MG、MA并进行分析比较。结果β2-MG在化疗后1d即开始升高，随后尿MA和血CysC均升高。化疗后尿β2-MG和尿MA及血清Cysc同化疗前相比有显著性差异。结论尿β2-MG及MA和血清CysC具有较好的早期肾损伤诊断价值，且较血BUN、Cr更灵敏。Objective To study the clinical significance of detecting the serum Cystatin C （CysC）, Microalbuminuria（MA）,β2-microglobin （β2-MG） and blood Urea （Urea）, Creatinine （Cr） in cancer patients treated with chemotherapy. Methods Serum level of CysC, MA,β2-MG and Urea, Cr were detected in 50 patients with malignant tumor at baseline and 1,3,7,15 days after treated with chemotherapy respectively. Their levels pre-and post-chemotherapy were analysed. Results serum level of β2-MG increased significantly at 1 d postchemotherapy; Urea MA and serum CysC incerased simultaneously in the following days. The levels of CysC, MA, β2-MG were significant higher than that at baseline. Conclusion Detecting the levels of CysC, MA, β2-MG had a higher valuation in early diagnosing renal function damage and are more sensitive than blood Urea and Cr in the early diagnosis of renal function damage.

关 键 词：尿Β2-微球蛋白 尿微量白蛋白 胱抑素C 恶性肿瘤 肾功能 

分 类 号：R587.2[医药卫生—内分泌]